Loading...
TRIOC-A randomised phase II trial to examine MVA-5T4 vaccine in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
Michael, A. Wilson, W. Harrop, R. McNeish, I. Lord, R. Blount, D. Clamp, Andrew R Feeney, M. Farrelly, L. Hanna, L.
Michael, A.
Wilson, W.
Harrop, R.
McNeish, I.
Lord, R.
Blount, D.
Clamp, Andrew R
Feeney, M.
Farrelly, L.
Hanna, L.
Citations
Altmetric:
Abstract
Background: Continued surveillance is often used in patients with ovarian cancer who
have asymptomatic relapse. Immunotherapy directed at 5T4, an onco-foetal tumour
antigen (TAA) may contain the relapse and delay the need for further chemotherapy.
MVA-5T4 (TroVax ) consists of an attenuated Vaccinia Virus (Modified Vaccinia Ankara,
MVA) containing the gene encoding for the human TAA, 5T4. We examined whether
MVA-5T4 vaccination can delay tumour progression of relapsed ovarian cancer.
Methods: The trial started as a double-blind randomised phase II trial with placebo,
but an unforeseen interim trial suspension led to limited drug supply, so it later
changed to a single arm study. Eligible patients had asymptomatic (CA-125 rise onlyor
low volume disease) relapsed ovarian cancer; 6 months since prior chemotherapy
and ECOG 0-1. Primary endpoint was progression rate at 25 weeks (PR-25):
confirmed progression using RECIST and immune-related response criteria, clinical
intervention for symptoms of progression or death. We aimed to detect an
improvement in PR from 70% (placebo) to 50% (MVA-5T4).
Results: 94 eligible patients were recruited from 12 centres (11/13 to 11/17). There
were 69 randomised patients, 25 were added in a single arm study. Median age was
65 years (range 42 to 82), and median time since prior chemotherapy 18 months (7 to
86); median follow up 34 months (2 to 46). 22 patients were withdrawn from trial
treatments during the suspension. The PR-25 was similar: 80.0% (MVA-5T4) vs 82.9%
(placebo) p-0.74. In the pre-specified per protocol analysis (patients who had 5
treatment injections and were unaffected by trial suspension), the corresponding
rates were 78.8% and 90.9%. Median PFS was the same in both arms (3.0 months).
Median time to clinical intervention appeared to be improved with MVA-5T4 9.7 (6.7-
14.3) vs 6.1 (5.1-8.6), p-0.14. 27.6% (MVA-5T4) vs 22.9% (placebo) had a grade 3-4
adverse event. QoL was also similar in both arms.
Conclusions: MVA-5T4 vaccination in patients with asymptomatic relapse was welltolerated
but did not improve the progression rate at 25 weeks. Further immunological
analysis to identify subsets of patients who might benefit from MVA-5T4 is
ongoing.
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 85.4 KB
Keywords
Type
Meetings and Proceedings
Citation
Michael A, Wilson W, Harrop R, McNeish I, Lord R, Blount D, et al. 838P TRIOC-A randomised phase II trial to examine MVA-5T4 vaccine in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer. Annals of Oncology. 2020;31:S629-S.